According to reports from ET Now, Max Healthcare reported a 3% increase in network profit after tax to ₹387 crore in the fourth quarter ended March 31, 2026. The company's gross revenue for Q4 stood at ₹2,664 crore, representing a 10% growth over the same period of the previous fiscal. Bed occupancy for the quarter was at 75% with occupied bed days (OBDs) up by 8% YoY, while ARPOB (average revenue per occupied bed) for Q4 FY26 stood at ₹77,900 compared to ₹77,100 in Q4 FY25. The board of directors has recommended a final dividend of ₹2 per equity share for 2025-26. However, recent analysis reveals that while the company achieved record quarterly revenue of ₹2,142.89 crores with 12.21% YoY growth, this represents a deceleration from the company's historical five-year CAGR of 33.07%, suggesting a maturing business trajectory.
As reported by ET Now, operating profitability remained a bright spot with operating profit before depreciation, interest, and tax reaching ₹606.43 crores in Q4 FY26, yielding an operating margin of 28.30%—the highest quarterly margin in recent periods and up 226 basis points sequentially. This margin expansion reflects improved operational efficiency and better capacity utilisation across the hospital network. However, the net profit margin of 15.97% in Q4 FY26, while healthy, has shown volatility across quarters, ranging from 12.78% to 23.01% over the past seven quarters. A concerning trend emerged in the form of escalating interest expenses, which climbed to ₹66.66 crores in Q4 FY26—the highest quarterly interest burden recorded, representing a 11.71% sequential increase and reflecting the company's expanded debt profile.
As reported by ET Now, brokerage firm Nuvama has maintained a Buy rating with a target price of ₹1,023, citing the company's well-positioned volume-led growth prospects. The brokerage expects capacity to nearly double to ~9,400 beds in FY30E backed by ~70% brownfield expansion at high-occupancy hospitals. Emkay has retained an Add rating with a target price of ₹1,125, noting that the Q4FY26 results were largely in line with estimates as network revenue and EBITDA grew 10% and 18% YoY respectively. The brokerage expects 20% revenue CAGR over FY26-28E driven by OBD/ARPOB CAGR of 15%/5%.
According to ET Now, the company's board has approved an investment of ₹1,400 crore for construction of a 712-bed greenfield hospital at Shaheed Path, Lucknow. CMD Abhay Soi stated that the network delivered its 22nd consecutive quarter of year-on-year growth with revenue increasing by 10%. The company has commenced phased commissioning and ramp-up of brownfield expansions across Mohali, Mumbai and Delhi, representing approximately 20% capacity addition. For the financial year ended March 31, 2026, network gross revenue stood at ₹10,538 crore while network PAT after exceptional items stood at ₹1,631 crore in FY26, compared to ₹1,336 crore in FY25, up 22%.
As reported by ET Now, shares of Max Healthcare closed at ₹1,025.00 on Friday, up 0.17% from the previous close, but the stock has been under significant pressure, declining 6.17% in the latest trading session to ₹1,024.20, reflecting investor concerns about stretched valuations and moderating growth momentum. The stock has underperformed its sector peers by 30.62 percentage points over the past year, declining 11.09% compared to the Hospital sector's 19.53% gain. The company's proprietary Mojo Score of 42 out of 100 places it firmly in "SELL" territory, reflecting concerns about expensive valuations, flat near-term financial trends, and bearish technical momentum. The stock trades at 73x price-to-earnings ratio, representing a premium to the industry average P/E of 63x, with technical indicators showing the stock trading below all key moving averages and classified as "MILDLY BEARISH" with immediate support at ₹903.50.
